The Trump administration's 100% Section 232 tariff on imported patented drugs and their active pharmaceutical ingredients took effect at the end of September, splitting the biopharma sector into two cost regimes: large drugmakers with most-favored-nation (MFN) agreements now defer payment until early 2029, while smaller biotechs without those deals pay the levy immediately.

The tariff, announced in April 2026 after a Section 232 national security review, covers patented finished medicines and the chemical inputs that feed them. The White House offered two relief paths: commit to MFN pricing in the U.S. — matching the lowest price charged in other wealthy markets — or relocate manufacturing to American soil.

What the two-tier structure means in practice

Companies that signed MFN agreements were originally scheduled to begin paying duties in July. Under revised terms, the first payment slips to early 2029, leaving signatories — which include many of the largest U.S. drugmakers — temporarily outside the levy.

Companies without MFN agreements or U.S. manufacturing face the duty now. Industry trade representatives say many of those members have received limited federal guidance on exemption procedures, leaving R&D and supply-chain planners with no formal channel to seek relief.

How does this hit R&D budgets?

For R&D managers, the immediate question is which line items absorb the new cost: imported clinical trial comparators, contract-manufactured active ingredients, or finished commercial inventory once Phase 3 trials read out.

Smaller biotechs face a compressed decision matrix. Three paths are emerging:

• Pass tariff costs into gross margin, preserving clinical timelines but shortening runway
• Accelerate reshoring of contract manufacturing, raising near-term capex but limiting duty exposure
• Restructure the pipeline toward assets with smaller or U.S.-sourced API requirements

Large-cap manufacturers bought roughly two and a half years of cost certainty. The R&D consequence is downstream: MFN pricing compresses U.S. revenue per script, feeding back into the capital available for clinical programs and platform extensions.

What caveats should finance teams apply?

Section 232 tariff classifications shift with trade-remedy rulings and HTS code interpretation. "Active pharmaceutical ingredient" defers to FDA drug master file definitions that vary across biologics and small molecules. The 2029 deferral for MFN signatories holds under current agreement terms, but a change in trade policy or a failure to meet MFN compliance milestones could pull the date forward.

The carve-out also reshapes the contract development market. CDMOs with U.S. fill-finish or API capacity are likely to field inbound queries from smaller biotechs seeking relief, while overseas API-heavy suppliers face reduced order flow from U.S. sponsors.

What's the next data point to watch?

The first signal: a written exemption procedure from the U.S. Trade Representative's office or the Department of Commerce, with eligibility criteria smaller biotechs can model against. Until that guidance lands, smaller biotechs are pricing the full 100% levy into their cash-flow projections while large-caps operate against a 2029 deferred-payment schedule.

That split creates a planning asymmetry that R&D finance teams will need to model separately for every program touching imported API — with sensitivity bands calibrated to the announced tariff and to any enforcement escalation that hits small sponsors first.